Scientists have reported early results from a new gene editing treatment for a rare inherited immune disorder called p47-deficient Chronic Granulomatous Disease (p47-CGD). In this disease, a person's white blood cells cannot properly fight off certain infections. The study tested an experimental therapy, called PM359, which uses a precise gene editing technique called 'prime editing' to try to fix the genetic error in a patient's own blood stem cells. After receiving chemotherapy to prepare their body, two patients were given their own corrected cells back.
In both patients, the edited blood stem cells successfully engrafted, meaning they started producing new blood cells in the body. Most importantly, the corrected white blood cells, called neutrophils, showed restored activity of a crucial enzyme (NADPH oxidase) needed to kill germs. This restored activity was seen within one month and was still present at the last check-up, which was 6 months for one patient and 4 months for the other.
The main reason for caution is that this is a Phase 1 trial, which is the earliest stage of testing in humans. It involved only two participants and was primarily designed to look at initial safety. The side effects reported were consistent with the chemotherapy used, not necessarily the gene therapy itself. While these initial findings are encouraging for the field of gene editing, they are not proof that the treatment works. The results simply support moving forward with more research involving more patients over a longer time to truly understand the therapy's safety and long-term benefits.
